<DOC>
	<DOCNO>NCT01721018</DOCNO>
	<brief_summary>HSV1716 , oncolytic virus , mutant herpes simplex virus ( HSV ) type I , delete RL1 gene encodes protein ICP34.5 . Malignant mesothelioma aggressive , asbestos-related tumour pleural peritoneal cavity . It rare cancer occur individual expose asbestos , although typically occur decade exposure ( 10-40 year later ) . Malignant pleural mesothelioma form plaque distribute surface pleural space lung . Approximately 30 % patient require indwell pleural catheter drainage pleural effusion . In patient group , indwell catheter may use facilitate loco-regional delivery HSV1716 pleural space . This study seek evaluate safety biological effect single multiple administration HSV1716 treatment malignant pleural mesothelioma .</brief_summary>
	<brief_title>Intrapleural Administration HSV1716 Treat Patients With Malignant Pleural Mesothelioma .</brief_title>
	<detailed_description>The study conduct two part . PART A single centre , single dose design , open label . Patients inoperable malignant pleural mesothelioma receive single dose HSV1716 intrapleural administration . Delivery direct administration via indwell catheter pleural cavity . PART B single centre , repeat dose design , open label . Two group three patient inoperable malignant pleural mesothelioma receive 2 ( group 1 ) 4 ( group 2 ) single dos HSV1716 weekly interval . Administration via indwell catheter pleural cavity .</detailed_description>
	<mesh_term>Mesothelioma</mesh_term>
	<criteria>Patients histologically prove malignant pleural mesothelioma Patients disease amenable potentially curative resection Patients pleural effusion and/or 'trapped lung ' ( ) exist indwell pleural catheter drain excess pleural fluid ( ii ) require insertion indwell pleural catheter drain excess pleural fluid Patients performance status ≤ 2 ( ECOG ) Age ≥ 18 year ( screen ) Ability give write informed consent evidence signature patient consent form , communicate well investigator comply expectation study Patients likely require palliative radio chemotherapy within 30 day Any evidence uncontrolled cardiac respiratory disease would contraindication virus administration Any serious medical psychiatric disorder would contraindication virus administration Acute active infection kind severe systemic disease medical surgical condition deem significant principal investigator Patients immunosuppressive disorder systemic steroid &gt; 5mg prednisolone/day Pregnancy : woman childbearing potential take adequate contraception , woman breast feed Previous treatment investigational viral therapy product Administration unlicensed investigational product within 8 week entry study No prior concurrent malignancy within 5 year basal cell carcinoma skin situ neoplasia cervix uteri Inadequate haematological function define : Haemoglobin ( Hb ) &lt; 10g/dl , Neutrophil Count &lt; 1.5 x 10e9/l , Platelets &lt; 100 x 10e9/l Deranged liver function test : serum bilirubin ≥ 1.5 x upper limit normal reference range laboratory ; transaminases ≥ 5 x upper limit normal reference range Patients inadequate renal function : serum creatinine ≥ 1.5 x upper limit reference range laboratory Patients whose indwell catheter type approve sponsor use study Outwith inclusion criterion consider unsuitable entry study way discretion principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Oncolytic virus</keyword>
	<keyword>HSV1716</keyword>
	<keyword>Mesothelioma</keyword>
	<keyword>MPM</keyword>
	<keyword>Woll</keyword>
	<keyword>Sheffield</keyword>
	<keyword>Weston Park</keyword>
	<keyword>Virttu</keyword>
	<keyword>Crusade</keyword>
</DOC>